QI-019B

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameQI-019B
Drug Alias NameQI-019B
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A